Physician profile
Aliye Vayner
NPI 1710274238
$3,090.81
in general payments reported to CMS, 2019-2025
17 companies · $651 in 2025
The $651 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $19.40 · 2021: $346 · 2022: $586 · 2023: $591 · 2024: $512 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $722.91 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $377.60 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $365.69 | 2019-2025 | Acuvue |
| Allergan, INC. | $326.37 | 2021-2022 | |
| Alcon Vision LLC | $293.33 | 2019-2025 | Rocklatan, Eysuvis, Total30 |
| Bausch & Lomb Americas INC. | $160.28 | 2022-2025 | Infuse, Miebo, Xiidra |
| Sight Sciences, INC. | $155.83 | 2019 | |
| Glaukos Corporation | $141.15 | 2022 | |
| Sun Pharmaceutical Industries INC. | $118.98 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $109.76 | 2021-2023 | |
| Harrow Eye, LLC | $105.78 | 2025 | Vevye |
| Coopervision INC. | $90.41 | 2022-2023 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $42.32 | 2022 | |
| Lkc Technologies, INC. | $25.80 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.68 | 2022 | |
| Dompe US, INC. | $17.52 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliye Vayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.